StockNASDAQ · US · USDHealthcare · Medical Instruments & Supplies
$BNGO
Bionano Genomics, Inc.
Bionano develops and sells genome analysis systems, nucleic acid extraction and purification products, software, and diagnostic and laboratory services for researchers, clinicians, genomics laboratories, and pharmaceutical and biotechnology companies. Its Saphyr and Stratys systems use optical genome mapping to detect structural variation in chromosomes for research and clinical applications, including genetic disease, cancer, and cell and gene therapy. The systems use instruments, consumables, reagents, and analysis software. Bionano also sells the Ionic Purification system, which uses isotachophoresis to extract and purify DNA or RNA, and VIA software for analysis and interpretation of optical genome mapping, sequencing, and microarray data. Bionano earns money from sales of its systems, consumables, reagents, and software, including software sold on a pay-per-sample basis for sequencing and microarray users. Its Bionano Laboratories business provides optical genome mapping testing and laboratory services, including an LDT for facioscapulohumeral muscular dystrophy type 1. Laboratory services are performed in San Diego, California and, at times, partner laboratories in the United States and Europe. Bionano is headquartered in San Diego, California.
Bionano Genomics (BNGO) reported Q3 2026 earnings, highlighting 18% year-over-year growth in flow cell sales and 24% growth in consumable revenue. The company focuses on profitable growth, supporting existing users, and expanding OGM utilization. Key developments include Medicare coverage proposals and academic center adoptions, driving broader OGM adoption. Software revenue declined 31% due to fewer VIA licenses sold.
Bionano Genomics, Inc. (BNGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Bionano Reports Third Quarter 2026 Results and Provides a Business Update Conference call today, November 10, 2026, at 4:30 PM ET SAN DIEGO, November 10, 2026 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the third quar
Tyra Biosciences (TYRA) raised $400M via stock offering for clinical development, shares up 15%. Nasus Pharma (NSRX) cleared FDA IND for NS002, shares up 10%. Bionano Genomics (BNGO) peer-reviewed studies showed OGM's effectiveness, shares up 9%. Tenaya Therapeutics (TNYA) received FDA RMAT designation for TN-401, shares up 9%.
via TradingView
BNGO sentiment & insider activity
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning BNGO (Bionano Genomics, Inc.). Coverage has skewed bearish: 0 bullish, 4 neutral, and 1 bearish.
Recent BNGO coverage spans earnings, technology and financial news.
What's driving BNGO
Mixed earnings with strong consumable growth but weaker software sales; overall revenue growth may support modest upside.
AlphAI scores every news story that mentions BNGO with an AI model for sentiment and relevance, and aggregates insider trades from Bionano Genomics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Bionano Genomics (BNGO) reported Q3 2026 earnings, highlighting 18% year-over-year growth in flow cell sales and 24% growth in consumable revenue. The company focuses on profitable growth, supporting existing users, and expanding OGM utilization. Key developments include Medicare coverage proposals and academic center adoptions, driving broader OGM adoption. Software revenue declined 31% due to fewer VIA licenses sold.
Bionano Genomics, Inc. (BNGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Bionano Reports Third Quarter 2026 Results and Provides a Business Update Conference call today, November 10, 2026, at 4:30 PM ET SAN DIEGO, November 10, 2026 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the third quar
Tyra Biosciences (TYRA) raised $400M via stock offering for clinical development, shares up 15%. Nasus Pharma (NSRX) cleared FDA IND for NS002, shares up 10%. Bionano Genomics (BNGO) peer-reviewed studies showed OGM's effectiveness, shares up 9%. Tenaya Therapeutics (TNYA) received FDA RMAT designation for TN-401, shares up 9%.
Bionano Genomics (BNGO) reported that three studies showed its optical genome mapping (OGM) technology identified high-risk genomic alterations in blood cancers, often missed by standard methods. OGM detected significant variants in 15.9% of MDS cases and 46% of cytogenetically normal AML samples, impacting survival rates. The studies suggest OGM could improve risk stratification and treatment planning. BNGO shares are up 2.05% at $1.24.
Bionano Genomics (BNGO) reported Q2 2026 revenue of $8.2 million, up 21% year over year, driven by higher OGM consumables sales. Flow cell sales rose 27% to 9,219 units, though the company said it is backordered due to manufacturing constraints. Installed base was 397 systems. Adjusted gross margin was 53%. Full-year 2026 revenue guidance is $31 million to $33 million.
Bionano Genomics reported Q2 2026 results on an earnings call, citing 30% YoY consumables growth and record 53% adjusted gross margin from higher adoption and efficiency. Full-year 2026 revenue guidance was raised to $31M-$33M. Flow-cell backorders and manufacturing constraints are expected to ease by Q4 2026. Software revenue fell 16% YoY.
Bionano Genomics, Inc. (BNGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Bionano Reports Second Quarter 2026 Results and Provides a Business Update Conference call today, August 10, 2026, at 4:30 PM ET SAN DIEGO, August 10, 2026 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the second quarte
Bionano Genomics (Nasdaq: BNGO) said 13 studies published in 2026 covering 730 samples across multiple countries evaluated optical genome mapping (OGM) for structural-variant detection in reproductive health and prenatal genetic disorders. The company cited results including 1-in-4 diagnoses in unexplained infertility (220 subjects) and up to 99.03% prenatal concordance (217 samples).
Bionano Genomics director Kristiina Vuori, MD, was granted 9,149 stock options at an exercise price of $1.19 per share. These options, part of her compensation, will vest in equal monthly installments over 12 months or fully upon a Change of Control, and expire on May 13, 2036. This transaction is considered a neutral event in terms of filing impact and sentiment, as it represents equity compensation rather than an open-market purchase.
Bionano Genomics, Inc. (BNGO) reported a Q1 loss of $0.76 per share, outperforming the Zacks Consensus Estimate of a $0.81 loss and surpassing year-ago revenues. The company posted revenues of $6.69 million for the quarter ended March 2026, beating estimates by 2.88%. Despite an underperforming stock year-to-date, its earnings outlook is favorable, earning it a Zacks Rank #2 (Buy).
